[Prognostic value of prostatic acid phosphatase in stage B and C prostatic cancer. Apropos of 84 cases].
The authors have studied the prognostic interest of evaluating the prostatic acid phosphatase level before any treatment in 84 cases of stage B and C prostatic cancer. An abnormal PAP level did not significantly modify the 5-year life expectancy of patients, but was significantly correlated with a shorter period of disease-free survival. An abnormal PAP level increased the risk of recurrence; the higher the PAP level, the shorter the disease-free interval was. The disease stage (i.e., B or C) did not modify the 5-year survival period or the length of the remission. The prognosis is worse for a stage B prostatic cancer with a pathological PAP level than for a stage C cancer with a normal PAP level. A pathological PAP level seems to indicate the presence of occult metastases and should incite the clinician to actively investigate the matter.
Guerin
J L
JL
Département de biologie clinique, centre Claudius-Regaud, Toulouse, France.
Canal
P
P
Douchez
J
J
Soula
G
G
D000135:Acid Phosphatase / Q000097:blood*; D000206:Actuarial Analysis; D000230:Adenocarcinoma / Q000201:enzymology* / Q000453:epidemiology / Q000473:pathology / Q000532:radiotherapy; D000368:Aged; D006801:Humans; D008297:Male; D011379:Prognosis; D011467:Prostate / Q000201:enzymology*; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000453:epidemiology / Q000473:pathology / Q000532:radiotherapy; D012189:Retrospective Studies
D000135:Acid Phosphatase
Intérêt pronostique de la phosphatase acide prostatique dans les cancers de la prostate de stades B et C. A propos de 84 cas.